Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the 2011 American Society of Clinical Oncology Annual Meeting
Date:5/18/2011

SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGE® (sipuleucel-T) data presentations taking place at the 2011 American Society of Clinical Oncology annual meeting in Chicago, Illinois.

  • "Time to Disease-Related Pain After Sipuleucel-T in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Results from 3 Randomized Phase 3 Trials," abstract #4661. McCormick Place Hall A (Poster 12E) from 8:00 a.m. to 12:00 p.m. CT on Sunday, June 5, 2011.
  • "Quality of Life Assessment in Randomized, Double-Blind Study of Sipuleucel-T in Men with Androgen Dependent Prostate Cancer," abstract #4648. McCormick Place Hall A (Poster 10H) from 8:00 a.m. to 12:00 p.m. CT on Sunday, June 5, 2011.
  • "Post-Progression Treatment with APC8015F May Have Prolonged Survival of Subjects in the Control Arm of Sipuleucel-T Phase 3 Studies," abstract #4534. E450A from 2:00 to 6:00 p.m. CT on Saturday, June 4, 2011.
  • "Sipuleucel-T in African Americans: a Subgroup Analysis of Three Phase 3 Sipuleucel-T Trials in Advanced Prostate Cancer," abstract #E15148. Publication only.

PROVENGE was approved by the U.S. Food and Drug Administration (FDA) in April 2010 as the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

"In addition to the significant survival benefit PROVENGE has demonstrated in Phase 3 clinical trials, the data analyses presented at the 2011 ASCO annual meeting provide further insight into the immunotherapy's potential impact on patient sub-groups, as well as clinically important factors like time to disease-related pain and quality of life," said Mark Frohlich, M.D., executive vice president of research and develop
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Research and Markets has announced the addition ... Disease: A Comprehensive Analysis and Market Study of New ... This report is a comprehensive analysis ... minimally-invasive biomarkers in Alzheimer,s disease, which have been ,functionally ... AD drug pipeline, and applicable commercial AD diagnostics. ...
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... Leaders (KOLs) can be the difference between a product,s ... to effectively map and stratify KOL targets – and ... build the type of strong relationships upon which successful ... research, savvy pharma companies have identified internal inconsistencies in ...
(Date:8/29/2014)... DIEGO , Aug. 29, 2014   ... emerging biopharmaceutical company, announced today that Santosh Vetticaden, ... be leaving the Company, for personal reasons, in ... Chief Medical Officer of Aires Pharmaceuticals, which Mast ... former responsibilities as the Company,s interim Chief Medical ...
Breaking Medicine Technology:Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014 2Implementing a Strategic Thought Leader Management & Engagement System 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... Findings from an international,multicenter, randomized, double-blind, placebo-controlled Phase ... of moderate to severe,plaque psoriasis will be presented ... the World Congress of Dermatology, which takes place ... Aires, Argentina. The presentation, entitled CNTO 1275 ...
... Study Will Assess Drug,s Benefit, Alone and With Lipitor(R), ... Cholesterol and Triglycerides -, HAYWARD, Calif., Sept. 25 ... and development of novel,therapeutics for diabetes and related metabolic ... 2 trial of MBX-8025 in overweight or,obese patients with ...
Cached Medicine Technology:Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting 2Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia 2
(Date:9/2/2014)... At the 50th Annual Mr. Olympia ... an exhibitor at the Las Vegas Convention Center South ... 89109 Booth #374 Sept 19th and 20th 10am-5PM. ... through exercise, diet and supplementation. They pride themselves on ... tools for all Prosupps customers to reach their personal ...
(Date:9/2/2014)... Tuesday 2 September 2014: A simple awareness campaign ... (AF), according to research presented at ESC Congress today ... said: "Atrial fibrillation (AF) is the most common cardiac ... by three-fold and the risk of stroke risk by ... 1 of 4 cases. However, AF is often overlooked ...
(Date:9/2/2014)... 2 September 2014: The fact that mechanical heart valves ... by data from the ROPAC registry presented for the ... session by Professor Jolien W. Roos-Hesselink, co-chair with Professor ... found that 1.4% of pregnant women with a mechanical ... pregnancy. , The Registry Of Pregnancy And Cardiac disease ...
(Date:9/2/2014)... NOVAtime Technology, Inc. ( http://www.novatime.com ), a forward-thinking ... Avon Health Center, a long-time NOVAtime 3000 customer ... Time and Attendance / Workforce Management solution ... the NT7000 . , Avon Health Center in ... nursing facility that provides short-term rehabilitation, long-term care, ...
(Date:9/2/2014)... Productive Dentist Academy, a dental ... State, has been named to Inc. Magazine’s 5000 list ... the third year in a row it has obtained ... astonishing 63 percent growth rate and increased revenues from ... increased its number of employees from eight to 25. ...
Breaking Medicine News(10 mins):Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 2Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 3Health News:Dental Management Company Named to Fastest-Growing List Again 2Health News:Dental Management Company Named to Fastest-Growing List Again 3
... through which 3-month-old Jason Wolfe received a lung transplant, while ... // transplant in Ohio. The surgery was possible as a ... compatible to the two babies who were in need of ... lungs were transplanted to Jason, while the heart of Jason ...
... Centers for Disease Control and Prevention said that all samples ... to adamantanes, the class of drugs which is used for ... this class like amantadine and rimantadine are ineffectual for now ... ,The findings were reported in the Journal of the ...
... But now after bringing in changes in their sexual behavior, by ... and using condoms have greatly reduced the number of people suffering ... among women in the age group of 15-24 the prevalence of ... in the age group of 17-29. ,Hence the researcher, ...
... doesn’t seem to rest in the Asian peninsula. A new case ... died at Hasan Sadikin Hospital in the Indonesian town of Bandung.// ... WHO -accredited lab in Hong Kong it will become the 15th ... was a resident of Padalarang in Bandung regency, some150 km south ...
... suspected cases of bird flu have been reported in Iraq’s northern ... result of the disease. The // region’s diagnosis center has admitted ... virus. The Rania region of the north bordering Turkey is reported ... have spread from neighboring Turkey, which has seen four deaths and ...
... Severe earthquakes can result due to tectonic plates colliding with ... severe damage can be caused // by the subduction zone. ... The earth's surface is laced with about 51,000 kilometers of ... zones averages a slip of about two inches per year. ...
Cached Medicine News:Health News:Resistant Influenza strains creates panic in US 2
The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....
Setting a new standard in protective apparel. The unique, patented Cool-Tech™ mesh-back design fits the natural contour of the body while reducing the amount of weight carried on the shoulders ...
Apron,special Proceddure...
Crisscross shoulder design facilitates better posture and distributes weight to back and hips for greater comfort. Shoulder pads soften shoulder contact with apron for additional comfort....
Medicine Products: